<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3214">
  <stage>Registered</stage>
  <submitdate>28/06/2011</submitdate>
  <approvaldate>28/06/2011</approvaldate>
  <nctid>NCT01384682</nctid>
  <trial_identification>
    <studytitle>Maraviroc Switch Collaborative Study</studytitle>
    <scientifictitle>Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well-Controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of cART</scientifictitle>
    <utrn />
    <trialacronym>MARCH</trialacronym>
    <secondaryid>2011-01-MAR</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Maraviroc

No Intervention: No change - continue their current cART regimen

Active Comparator: Replace N(t)RTI drugs with Maraviroc - Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r

Active Comparator: Replace PI/r drugs with Maraviroc - Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.


Treatment: drugs: Maraviroc
Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The comparison of the switch arms to control arm of proportions of participants with HIV RNA &lt;200 copies/mL 48 weeks after randomisation.</outcome>
      <timepoint>48 weeks after randomization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Virological endpoints: proportion of participants with plasma HIV-1 RNA&lt;50 copies/ml - A number of secondary endpoints will be examined at or through to week 48 in this protocol. These will include, but not be limited to the following:
Virologic; Immunologic and biomarkers; Clinical; Metabolic and body composition; Safety; Adherence; Quality of Life and Resistance endpoints.</outcome>
      <timepoint>48 weeks from randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Documented HIV-1 infection by a licensed diagnostic test at any time prior to study
             entry

          -  Age &gt;18 years

          -  HIV-1 RNA &lt;200 copies/mL plasma for at least 24 weeks

          -  Stable (&gt;24 weeks) ART including two N(t)RTIs and a PI/r

          -  No evidence of any primary HIV genotypic mutations in HIV reverse transcriptase or
             protease for all patients with available resistance testing results conducted prior to
             cART and/or during viral rebound/failure

          -  Provision of written, informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  CXCR4 or CCR5/CXCR4 dual tropic HIV tropism or a non-reportable tropism result based
             on assessment using proviral DNA

          -  Anticipated need to modify current cART regimen for toxicity management in the next 6
             months

          -  The following laboratory criteria,

               1. absolute neutrophil count (ANC) &lt;750 cells/µL

               2. haemoglobin &lt;8.0 g/dL

               3. platelet count &lt;50,000 cells/µL

               4. serum AST, ALT &gt;5 x upper limit of normal (ULN)

          -  Active hepatitis B co-infection

          -  Pregnant women or nursing mothers

          -  Current use of any prohibited medications as described in product specific
             information.

          -  Hypersensitivity to soy or peanuts

          -  Acute therapy for serious infection or other serious medical illness (in the judgement
             of the site Principal Investigator) requiring systemic treatment and/or
             hospitalisation

          -  Use of immunomodulators (e.g. systemic corticosteroids, recombinant interleukin-2,
             interferon) within 30 days prior to screening

          -  Patients with current alcohol or illicit substance use that in the opinion of the site
             Principal Investigator would conflict with any aspect of the conduct of the study

          -  Patients unlikely to be able to remain in follow-up for the protocol-defined period

          -  Prisoners or subjects who are compulsorily detained (involuntary incarcerated).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>399</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Holdsworth House Medical Practice - Sydney</hospital>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <hospital>Gladstone Road Medical Centre - Bisbane</hospital>
    <hospital>Brisbane Sexual Health and HIV Service (formerly AMU) - Brisbane</hospital>
    <hospital>Nambour General Hospital - Nambour</hospital>
    <hospital>O'Brien Street Practice - Adelaide</hospital>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2145 - Sydney</postcode>
    <postcode>4101 - Bisbane</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>4560 - Nambour</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Provincia de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Provincia de Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Orleans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagoya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Leon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalonia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lothian</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sussex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Warwickshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>ViiV Healthcare</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Pfizer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>MARCH is an international, multicentre trial planning to enroll 380 HIV-1 infected patients
      who are currently on 2N(t)RTI + PI/r regimen and virologically suppressed. Participants will
      be randomized (1:2:2) to one of three treatment groups: to continue their current treatment
      regimen, maraviroc dose at 150 mg twice daily with PI/r, or maraviroc at 300 mg twice daily
      with 2N(t)RTI. As the participants population have HIV RNA &lt;200 copies/mL, the phenotypic
      assessment of tropism cannot be used to determine tropism, instead we will employ the
      genotypic assessment of tropism by sequencing the V3 loop of the HIV envelope. The main aim
      of this study is to investigate whether switching to maraviroc, in combination with either
      RTI or PI/r, is as good at keeping the HIV viral load undetectable as the combination of RTI
      with PI/r. The other aim is to see if switching to these combinations with maraviroc will
      improve some of the side effects that can be seen when people take combination therapy
      including RTI and PI/r.

      The study hypothesis is that in stable, virologically suppressed (plasma HIV-RNA &lt;200
      copies/mL) patients with no history of prior virological failure, a switch to either MVC
      dosed at 300mg twice daily (bid) combined with the same 2N(t)RTI backbone regimen or MVC
      dosed at 150mg twice daily (bid) with the current PI/r (or 300mg bid at the discretion of the
      investigator if the PI/r is fosamprenavir/r) provides similar (non-inferior) antiretroviral
      efficacy compared to continuation of the current 2N(t)RTI + PI/r regimen.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01384682</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David A Cooper, AO</name>
      <address>Kirby Institute, University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>